Formation Bio raises a $600 million fund to buy the drugs other companies gave up on

Formation Bio said Wednesday, Oct. 28, 2026, that it has $600 million in commitments for its new Drug Development Accelerator Fund, which will acquire clinical-stage drug programs and push them through key trials using the company's AI development platform.

Most AI-pharma pitches promise to invent new molecules. Formation Bio is betting the money is in the boring, expensive part — running trials on drugs that already exist but got stranded in somebody else's pipeline when budgets moved. A $600 million fund backed by endowments and hospitals says serious capital buys that thesis, and the one-company-per-drug structure lets investors back a single asset instead of a whole biotech. The skeptic's question is simple: if AI makes development that much cheaper, the results will show up in trial readouts over the next two to four years, not in fund announcements. Until then it's a smart financing structure with an AI story attached.

Formation Bio, which calls itself an AI-native pharmaceutical company, announced the Formation Bio Drug Development Accelerator Fund on Oct. 28, 2026, with $600 million in capital commitments. A capital commitment is money investors have pledged. AI-native, here, means the company builds its drug work around its own AI tools, not a lab that added a chatbot later. Those lines are Formation Bio's, from its press release on PR Newswire.

The fund is meant to help the company acquire 10 to 15 drug programs over the next three to five years and push them through key clinical milestones. A clinical milestone is a result in a trial that shows the drug is worth taking further. That goal is Formation Bio's.

Formation Bio acquires or in-licenses Phase 1 and Phase 2 programs from pharma companies and biotechs. In-license means it pays for the right to develop a drug someone else already started. Phase 1 is the first test in people, usually to see if the drug is safe. Phase 2 is the next test, usually to see if it works. The company focuses on diseases with a real unmet need but little active work underway, and it aims for a major clinical milestone within two to four years of taking each program on. After meaningful clinical progress, it expects to partner the programs with pharma companies for commercialization, which is getting an approved drug to patients and to market. Those lines are Formation Bio's.

The fund's limited partners include research foundations, institutional endowments, hospitals, and philanthropic organizations. A limited partner puts money in and does not run the fund. Formation Bio is the general partner, the firm that does run it, through a wholly owned subsidiary, and it has committed its own capital alongside them. Those lines are Formation Bio's.

Each funded program sits in its own standalone company. That keeps each drug's economics separate, while the programs share Formation Bio's development organization instead of standing up a new staff for every asset. An asset, here, is one drug program. That structure is Formation Bio's.

Co-founder and chief executive Benjamine (Ben) Liu said the fund gives limited partners access to "individual drug assets" as an investment category, expands how many drugs Formation can pursue, and "creates paths to liquidity without selling the parent company." Liquidity, here, means a way for an investor to get cash back. Those quotations are his, on the release.

Forbes framed the bet this way: most AI drug companies focus on discovery, the hunt for a new molecule. Formation Bio argues the real bottleneck is clinical development, the trials that decide whether a drug already in hand is worth finishing. That framing is Forbes's, in its Oct. 28 story.

The picture is Formation Bio co-founder and chief executive Ben Liu, in a black sweater, seated against a mottled gray wall, with his reflection in a glass panel beside him. The credit is Guerin Blask for Forbes.

In plain terms, Formation Bio said on Wednesday that investors have pledged $600 million to a fund that will buy stalled Phase 1 and Phase 2 drugs and run the next trials. The plan is 10 to 15 programs over three to five years. Foundations, endowments, and hospitals are among the backers. Each drug sits in its own company. The chief executive says an investor can back one asset, and have a path to cash, without buying the whole firm.